# Omega 3 - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Omega 3 is supported by targeted clinical literature modulating longevity biomarkers.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **92/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 98/100
- **Primary Longevity Classification**: other
- **Safety Margin Score**: 76/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: moderate
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Operates via multi-target metabolic, mitochondrial, and cellular homeostatic pathways.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: Refer to individualized clinical assessment
- **Recommended Timing**: anytime
- **Administration Type**: lifestyle
- **Recommended Biomarkers to Monitor**: Metabolic and inflammatory panel

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: None reported in standard human trials with recommended doses.
- **Safety Profile**: High Margin - Well tolerated within physiological ranges.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT Trial)** [PMID: 30415628]
   - Link: https://pubmed.ncbi.nlm.nih.gov/30415628/
2. **Blood n-3 fatty acid levels and total and cause-specific mortality with 100,000 person-years of follow-up: the FORCE consortium** [PMID: 34707096]
   - Link: https://pubmed.ncbi.nlm.nih.gov/34707096/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Omega 3 on LongevityReviews](https://longevityreviews.org/modalities/omega-3)
- **Last Evidence Calibration**: 2026-09-16
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.